Prelude Capital Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Prelude Capital Management’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-53,964	Closed	-$114K	–	2442
2018 Q3	$114K	Buy	+53,964	New	+$129K	0.01%	925
2017 Q1	–	Sell	-656	Closed	-$5K	–	2004
2016 Q4	$5K	Sell	656 -3,244	-83%	-$29.8K	﹤0.01%	1446
2016 Q3	$45K	Buy	+3,900	New	+$45.4K	﹤0.01%	1077
2014 Q2	–	Sell	-1,100	Closed	-$37K	–	2474
2014 Q1	$37K	Buy	+1,100	New	+$37.1K	0.01%	1440

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Prelude Capital Management's OMED Position: Q4 2018 in Review

Prelude Capital Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 53,964 shares — an estimated $114K sold.

Prelude Capital Management first reported a position in OMED in Q1 2014 and held it in 4 quarters. The position peaked at $114K in Q3 2018. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

Prelude Capital Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Prelude Capital Management sold 53,964 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $114K.
Prelude Capital Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2014 and held it in 4 quarters.
Prelude Capital Management's OncoMed Pharmaceuticals, Inc. position peaked at $114K in Q3 2018.
42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.